Improving Osteoarthritis Diagnosis Through a More Accurate Blood Test

“It’s a chicken-and-the-egg predicament,” Kraus said. “In the immediate future, this new test will help identify people with high risk of progressive disease — those likely to have both pain and worsening damage identified on X-rays — who should be enrolled in clinical trials. Then we can learn if a therapy is beneficial.”

Revolutionizing Osteoarthritis Diagnosis

Kraus and colleagues isolated more than a dozen molecules in the blood associated with the progression of osteoarthritis, which is the most common joint disorder in the United States. It afflicts 10% of men and 13% of women over the age of 60 and is a major cause of disability.

With further honing, the researchers narrowed the blood test to a set of 15 markers that correspond
to 13 total proteins. These markers accurately predicted 73% of progressors from non-progressors among 596 people with knee osteoarthritis.

The prediction rate for the new blood biomarker was far better than the current approaches. Assessing baseline structural osteoarthritis and pain severity is 59% accurate, while the current biomarker testing molecules from urine is 58% accurate.

The new, blood-based marker set was also successfully identifying the group of patients whose joints show progression in X-ray scans, regardless of pain symptoms.

“In addition to being more accurate, this new biomarker has an additional advantage of being a blood-based test,” Kraus said. “Blood is a readily accessible biospecimen, making it an important way to identify people for clinical trial enrollment and those most in need of treatment.”

Source: Eurekalert